Marilyn will continue to fight to strengthen protections for people with preexisting conditions and end surprise billings, and she will continue to advocate patent reform so generic drugs can come to market more quickly, which will lower the cost of prescriptions.
Advocate patent reform so generic drugs can reach the market more quickly.
Occurrences
Marilyn will work to enact patent reform to get generic drugs to market quickly, lowering the cost of life-saving medication.
Evidence
The official press release archive on Rep. Strickland's House site shows its most recent item as Apr. 17, 2026 ('Strickland Introduces Bill Addressing Toxic Chemical Killing Pacific Northwest Salmon'). No press release entries in the archive fall inside the 2026-05-15 to 2026-06-13 lookback window, and none of the visible items reference patent reform or generic-drug market access.
The official health archive shows its latest visible entries on Oct. 31, 2025 and earlier, with topics including shutdown impacts, health insurance, and other health-related coverage. The archive does not show any recent 2026-05-15 to 2026-06-13 item about patent reform, generic drugs, or related drug-competition policy.
Assessments
Strickland’s campaign health-care priorities page shows same-term work on related prescription-drug affordability issues, including support for Medicare drug-price negotiation and a vote for insulin price caps. But the specific promise was to advocate patent reform so generics reach market faster, and the available federal-office evidence is weaker on that narrower point: her official House health and press-release archives through June 13, 2026 do not show patent-reform or generic-market-access advocacy, and accessible Congress.gov member-activity pages do not show an obvious patent/generic-titled bill she sponsored or cosponsored. That supports some credit for adjacent drug-pricing action, but not full delivery of the specific patent-reform promise.